However, acetylcholinesterase (AChE) inhibitors that block cholinergic degeneration of ACh are considered a promising approach in the treatment of AD and are currently approved by the FDA for use in AD to delay the progression of the disease [4]. This evidence concerns the gene ACHE and Alzheimer disease.